Grand Medical Group

About us

Grand Medical Group AG is a group of pharmaceutical companies specialized in the development, production, registration and introduction into medical practice of modern innovative products based on organic, synthetic and herbal compounds.

read more

10 Kornmarkt Street, CH - 6004 Luzern, Switzerland

info@grandmedicalgroup.ch

+41 415880810

CHOLOGRAND

Ursodeoxycholic acid
Fumitory
(Fumaria o?cinalis L., herba) standardized extract
L-ornithine-L-aspartate

HEALTH BENEFITS OF USE

CHOLOGRAND is recommended as a health supplement to the diet as an additional support for normalization of the secretion of bile and biliary tract motility, prevent the formation of cholesterol stones in the gallbladder, for the prevention of toxic liver damage (including drugs (contraceptives and cytotoxic drugs). Ursodeoxycholic acid (UDCA) reduces synthesis of cholesterol in the liver, its absorption in the intestine and its concentration in the bile, increases the solubility of cholesterol in the bile duct, and in this way, stimulates the formation and secretion of bile. UDCA reduces lithogenic properties of bile, increases in bile the amount of bile acids; stimulates gastric and pancreatic secretion. Fumaria o?cinalis extract contains alkaloids fumaryn which normalizes bile secretion in liver, lowers the tone of the sphincter of Oddi, supporting normal digestion via bile and pancreatic juice penetration into intestine. Amino acids ornithine and aspartate provide physiological detoxi?cation of ammonia through the synthesis of urea and glutamine in liver cells. In this way L-ornithine and L-aspartate (LOLA) increases the generation of urea via the urea cycle metabolism, in which ammonia is turned into neutral substance - urea and removed out of the organism.

AREAS OF APPLICATION – as a support

• In complex therapy of people with condition where the bile ducts in the liver become damaged, leading to a build-up of bile for support of the healthy liver and gallstone function;

• In complex therapy of people with not-radiopaque cholesterol gallstones no larger than 15 mm in diameter in patients with a functioning gallbladder for support of the healthy liver and gallstone function;

• In complex therapy of people with liver disease associated cystic ?brosis for support of the healthy liver function;

Gastroenterology